Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

QS21

Other · Immune activation · developed by Agenus

Phase 2 Most advanced trial (none active)

AGEN Developer

1 Registered trials

What is QS21?

QS21 is a purified natural saponin isolated from the soapbark tree with immunoadjuvant activity. When co-administered with vaccine peptides, it enhances antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses. It is studied in herpes simplex type 2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Mechanism: Immune activation
Therapy area: Infectious disease
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 61H83WZX3U

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01687595	Phase 2	Herpes Simplex Type 2	Completed	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Herpes Simplex Type 2

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 AGEN2373 Phase 1/2 Balstilimab Phase 2/3 BMS-986442 Phase 1 Botensilimab Phase 2/3 Vitespen Phase 2 Zalifrelimab Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind QS21

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z